Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.

Blood. 2009 Jun 11;113(24):6069-76. doi: 10.1182/blood-2009-01-199679. Epub 2009 Apr 20.

2.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

3.

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.

J Clin Oncol. 2008 Oct 1;26(28):4587-94. doi: 10.1200/JCO.2007.15.9277. Epub 2008 Jul 28.

PMID:
18662967
4.

Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.

Lanic H, Mareschal S, Mechken F, Picquenot JM, Cornic M, Maingonnat C, Bertrand P, Clatot F, Bohers E, Stamatoullas A, Leprêtre S, Rainville V, Ruminy P, Bastard C, Tilly H, Becker S, Vera P, Jardin F.

Leuk Lymphoma. 2012 Jan;53(1):34-42. doi: 10.3109/10428194.2011.600482. Epub 2011 Aug 1.

PMID:
21806349
5.

The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.

Mozos A, Roué G, López-Guillermo A, Jares P, Campo E, Colomer D, Martinez A.

Am J Pathol. 2011 Nov;179(5):2601-10. doi: 10.1016/j.ajpath.2011.07.031. Epub 2011 Sep 9.

6.

Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?

Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, Mian M.

Oncologist. 2016 Sep;21(9):1107-12. doi: 10.1634/theoncologist.2016-0103. Epub 2016 Jul 5.

7.

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.

Yoon N, Ahn S, Yong Yoo H, Jin Kim S, Seog Kim W, Hyeh Ko Y.

Oncotarget. 2017 Mar 28;8(13):22014-22022. doi: 10.18632/oncotarget.15782.

8.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

9.

Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.

Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS.

Leuk Lymphoma. 2014 Feb;55(2):415-24. doi: 10.3109/10428194.2013.806799. Epub 2013 Jun 24.

PMID:
23697845
10.
11.

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.

Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC.

Clin Cancer Res. 2009 Sep 1;15(17):5494-502. doi: 10.1158/1078-0432.CCR-09-0113. Epub 2009 Aug 25.

12.

[PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS].

Škunca Z, Planinc-Peraica A.

Acta Med Croatica. 2015 Mar;69(1):25-32. Croatian.

PMID:
26606782
13.
14.

ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?

Nowakowski GS, Czuczman MS.

Am Soc Clin Oncol Educ Book. 2015:e449-57. doi: 10.14694/EdBook_AM.2015.35.e449. Review.

15.

Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.

Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A, Alvarez R, Gomes da Silva M, Cabeçadas J, Calaminici M, Gribben JG.

Clin Cancer Res. 2013 Dec 15;19(24):6686-95. doi: 10.1158/1078-0432.CCR-13-1482. Epub 2013 Oct 11.

16.

The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.

Ruminy P, Etancelin P, Couronné L, Parmentier F, Rainville V, Mareschal S, Bohers E, Burgot C, Cornic M, Bertrand P, Lenormand B, Picquenot JM, Jardin F, Tilly H, Bastard C.

Leukemia. 2011 Apr;25(4):681-8. doi: 10.1038/leu.2010.302. Epub 2011 Jan 14.

PMID:
21233831
17.

FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

Brown PJ, Wong KK, Felce SL, Lyne L, Spearman H, Soilleux EJ, Pedersen LM, Møller MB, Green TM, Gascoyne DM, Banham AH.

Leukemia. 2016 Mar;30(3):605-16. doi: 10.1038/leu.2015.299. Epub 2015 Oct 26.

18.

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Camicia R, Winkler HC, Hassa PO.

Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2. Review.

19.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.

J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.

PMID:
25135992
20.

Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.

van Galen JC, Muris JJ, Giroth CP, Vos W, Ossenkoppele GJ, Meijer CJ, Oudejans JJ.

Histopathology. 2008 Apr;52(5):578-84. doi: 10.1111/j.1365-2559.2008.02970.x. Epub 2008 Feb 23.

PMID:
18312353

Supplemental Content

Support Center